Congestive Heart Failure Treatment Devices Market Study Explores Industry Growth Toward $30.06 Billion

The market for congestive heart failure treatment devices is poised for significant expansion over the coming years, driven by ongoing advancements and growing patient needs. As heart failure continues to affect an increasing number of people globally, the demand for effective and innovative treatment solutions is rising, shaping the future landscape of this medical device segment.

Strong Growth Outlook for the Congestive Heart Failure Treatment Devices Market Size Through 2030
The congestive heart failure treatment devices market is forecasted to reach $30.07 billion by 2030, growing at a compound annual growth rate (CAGR) of 7.2%. This robust growth stems from multiple factors including an aging population that faces higher risks of heart failure, a rising preference for minimally invasive cardiac treatments, and an intensified focus on early diagnosis and disease management. Additionally, increased accessibility to advanced heart failure therapies in emerging economies and wider use of long-term mechanical circulatory support devices further contribute to market expansion. Key trends influencing this growth period include greater adoption of advanced implantable heart failure devices, expanded use of ventricular assist devices in severe congestive heart failure cases, initiatives aimed at lowering heart failure-related hospital admissions, broader implementation of device-based therapies for sustained cardiac support, and a growing demand for continuous cardiac monitoring and management tools.

Download a free sample of the congestive heart failure treatment devices market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15774&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Jul_PR

Leading Players Driving the Congestive Heart Failure Treatment Devices Market
Several prominent companies are at the forefront of the congestive heart failure treatment devices market, including Medtronic plc, Abbott Laboratories, Boston Scientific Corporation, Biotronik SE & Co KG, LivaNova PLC, Berlin Heart GmbH, Jarvik Heart Inc, ReliantHeart Inc, Abiomed Inc, Lepu Medical Technology Co Ltd, Magenta Medical Ltd, MicroPort Inc, EBR Systems Inc, Syncardia Systems LLC, Oscor Inc, OSYPKA Medical GmbH, Calon Cardio-Technology, CoreWave SA, and Zoll Medical Corporation.
In a significant move within the industry, Johnson & Johnson, based in the United States, completed its acquisition of V-Wave Ltd. in October 2024 for an undisclosed sum. This strategic acquisition aims to enhance Johnson & Johnson's cardiovascular product lineup by incorporating V-Wave's pioneering interatrial shunt technology, which is designed to decrease left atrial pressure in patients suffering from advanced heart failure. V-Wave Ltd. is an Israel-based company specializing in medical devices for congestive heart failure treatment.

Trends Positively Impacting Market Growth Through Innovation
Leading companies are focusing on creating novel solutions such as the implant-free atrial septostomy system, which is designed to provide hemodynamic relief with less procedural complexity and fewer invasiveness concerns. This device creates a controlled opening in the atrial septum without leaving behind a permanent implant, improving the management of elevated left atrial pressure and enhancing cardiac function in heart failure patients.
For example, in January 2025, US-based Alleviant Medical Inc. achieved important FDA milestones for its innovative no-implant interatrial shunt device. This minimally invasive treatment option reduces pressure in the left atrium by forming a precise shunt that does not require permanent implantation. The approach reduces risks linked to implanted devices while ensuring long-lasting shunt openness, resulting in symptom relief, improved exercise capacity, and better quality of life for patients with chronic heart failure. Its goal is to support the heart, ease symptoms, and offer a safer alternative for patients with limited treatment options.

View the full congestive heart failure treatment devices market report:
https://www.thebusinessresearchcompany.com/report/congestive-heart-failure-treatment-devices-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Jul_PR

How the Congestive Heart Failure Treatment Devices Market is Categorized
This market is segmented by product, application, and end-user.
By product category, key devices include Cardiac Pacemakers, Implantable Cardioverter Defibrillators (ICDs), Cardiac Resynchronization Therapy Devices (CRT), Counter Pulsation Devices, and Ventricular Assist Devices (VADs).
Within application, the market differentiates between Left Ventricular Assist Devices (LVAD), Right Ventricular Assist Devices (RVAD), and Biventricular Assist Devices (BIVAD).
End-users primarily encompass Hospitals and Clinics, Specialized Cardiovascular Disease Treatment Centers, and Ambulatory Surgery Centers.
Further breakdowns include:
- Cardiac Pacemakers: Single Chamber, Dual Chamber, and Biventricular Pacemakers
- Implantable Cardioverter Defibrillators (ICDs): Traditional ICDs, Subcutaneous ICDs, and CRT-D (Cardiac Resynchronization Therapy Defibrillator)
- Cardiac Resynchronization Therapy Devices (CRT): CRT-P (Pacemaker) and CRT-D (Defibrillator)
- Counter Pulsation Devices: Intra-Aortic Balloon Pumps (IABP), External Counterpulsation Devices (ECP)
- Ventricular Assist Devices (VADs): Left, Right, and Biventricular Assist Devices

This detailed segmentation provides a comprehensive view of the market's diverse offerings and the various patient needs addressed by these advanced treatment devices.

Key enhancements in our 2026 market reports include:

• Market attractiveness scoring and analysis
• Total addressable market (TAM) analysis
• Company scoring matrix graphics and tables
• Excel-based forecasting dashboards
• Market hotspots infographics
• Key technologies and future trend analysis
• Updated graphics and tables

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 30,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.